include the predisposition to hypertriglyceridemia of patients with type 2 diabetes [5] , and poor tolerance of these drugs. Colestimide is a new anion exchange resin that has shown a strong lipid-lowering effect in rabbits [6] . It also achieves better patient compliance [7] , so colestimide has essentially replaced cholestyramine for the treatment of hypercholesterolemia in Japan. Cholestyramine has been reported to reduce the blood glucose level, but the influence of colestimide on glycemic control in diabetic patients has not been properly assessed. We previously reported that colestimde significantly reduced HbA1c in patients with type 2 diabetes [8] . Kondo also reported that colestimide monotherapy could significantly improve glycemic control in type 2 diabetic patients [9] . Considering that patients with type 2 diabetes also often have hyperlipidemia, colestimide therapy has the potential for a clinically useful dual action in such patients. However, to the drawn from an antecubital vein. HbA1c levels were measured by high performance liquid chromatography. The value for HbA1c (%) is estimated as an NGSP equivalent value (%) calculated by the formula HbA1c (%) = HbA1c (JDS)(%) + 0.4%, considering the relational expression of HbA1c (JDS)(%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) [10] . Plasma glucose levels were measured by the glucose oxidase method. Serum total cholesterol (T-chol), triglycerides (TG), and HDL-cholesterol were measured by standard enzymatic methods. LDL-C was measured with a direct LDLcholesterol assay kit (choletest-LDL, Sekisui Medical Co.) at SRL Inc. (a contract laboratory).
Statistical analysis
All data are shown as the mean SD. Statistical analyses were performed with SPSS software (version 16). Categorical data were tabulated as frequencies and percentages and were compared by using the χ 2 test or Fisher's exact test. Multiple regression analysis was employed to evaluate determinants of the decrease in HbA1c, and P values of less than 0.05 were considered statistically significant.
Results

Baseline characteristics
Assessment of the baseline characteristics of the patients showed that there were significant differences of age and body weight among the groups. The colestimide group was younger and the body weight of the pravastatin group was significantly lower compared with the other groups. In addition, random blood glucose level was not significant different between groups, but HbA1c of the colestimide group was significantly lower compared with the other groups.
No significant differences in the dosing changes of hypoglycemic drugs were found among the four groups. Use of other medications that could possibly affect glucose metabolism, such as antihypertensive drugs, also did not differ significantly among the four groups (Table 1) .
Therapeutic efficacy
There were no changes of antidiabetic drug doses for 71 patients in group Co, 71 patients in group Pr, and 76 patients in group Pi, and 74 patients in group At. Among these patients, the random blood glucose level best of our knowledge, no studies have been performed in diabetic patients to assess the effect of colestimide on clinical variables and laboratory parameters of glucose metabolism. Evaluation of the effect of colestimide therapy on factors that influence glucose metabolism may help us to understand the mechanisms through which this drug exerts a glucose-lowering action.
Accordingly, the aim of this study was to determine whether BMI or other clinical factors had an influence on the effect of colestimide on hemoglobin A 1c in patients with type 2 diabetes.
Materials and Methods
Patients with type 2 diabetes and hyperlipidemia who were receiving treatment with an HMG-CoA reductase inhibitor or colestimide at Yokohama City University Medical Center were enrolled in a retrospective study. All patients in this study started treatment with one of four different lipid-lowering drugs colestimide (group Co), pravastatin (group Pr), atorvastatin (group At) or pitavastatin (group Pi) between January 2002 and July 2009.
The drugs given to each patient were decided by the physician in charge. Patients in whom HbA1c showed a change of more than 10% within the preceding 3 months were excluded. As shown in Fig. 1 , the HbA1c values at baseline and 3 months before initiation of the study did not differ significantly among the four groups.
First, it was determined whether or not patients required an increase or reduction in the doses of their antidiabetic drugs (insulin and oral hypoglycemic agents) during the first 3 months of lipid-lowering therapy. Only patients who did not require any changes of drug dosage were then assessed for changes of random blood glucose and HbA1c during this 3-month period. Patients were excluded from the study if there had been any change in the doses of their antidiabetic drugs, if their medications had been altered within 3 months prior to the initiation of statin therapy, and if they were new patients presenting for the first time. Patients who experienced events that could alter glycemic control, such as hospitalization or intercurrent disorders, during the 3-month observation period were also excluded. Medications that are known to influence glucose tolerance or lipid metabolism could not be added or withdrawn during the study.
Institutional review board approval of the study was obtained and it was carried out in accordance with the Declaration of Helsinki. Blood samples were with-
Variables associated with a significant HbA1c-lowering effect of colestimide
By multivariate logistic regression analysis, we examined variables that could be associated with reduction of HbA1c by >0.5%. Variables included in the model were age, sex, BMI, baseline T-chol and TG levels, HbA1c, and lipid-lowering drugs. Colestimide therapy and baseline HbA1c were both independently associated with a >0.5% HbA1c-lowering effect. Other than lipid-lowering drugs, baseline HbA1c was the only independent variable and the age, sex, BMI, and basal lipid levels were not associated with the HbA1c-changed from 169 ± 59 to 138 ± 29 mg/dL in group Co, from 126 ± 21 to 124 ± 32 mg/dL in group Pr, from 155 ± 53 to 154 ± 51 mg/dL in group Pi , and from 147 ± 51 mg/dL (mean ± SD) to 176 ± 69 mg/dL in group At (Table 2 ). HbA1c changed from 8.1 ± 1.0% to 7.0 ± 0.8% in group Co, from 7.3 ± 0.9% to 7.3 ± 1.0% in group Pr, from 7.7 ± 1.0% to 7.6 ± 1.1% in Group Pi, and from 7.4 ± 1.1 % to 7.8± 1.3% in Group At. HbA1c and glucose levels both decreased significantly in group Co, but increased significantly in group At. lowering effect of colestimide and found that the baseline HbA1c level was the most important independent variable associated with this effect.
Another bile acid sequestrant (colesevelam hydrochloride) has been approved as an adjunct to antidiabetic therapy for improving glycaemic control in adults with type 2 diabetes. However, colestimide have not been approved in either the U.S.A. or Japan for treatment of diabetes. Therefore, there have only been a few studies on the use of colestimide in patients with diabetes. It should be clinically useful to identify the patients in whom colestimide therapy is more likely to be effective. As shown in the present study, baseline HbA1c was the most important predictor of the effectiveness of colestimide therapy. This finding is compatible with a previous report that the DPP-IV inhibitor sitagliptin also showed a significant interaction between baseline HbA1c and treatment effect [11] . All of the diabetic patients in our study also had hyperlipidemia, so colestimide therapy might be useful for any diabetic patient with hyperlipidemia.
The mechanism(s) by which colestimide lowers glucose in patients with type 2 diabetes is not yet clearly understood. However, there is increasing evidence that this effect of bile acid sequestrants may be mediated through the farnesoid X receptor (FXR/bile acid receptor), liver X receptor, and the influence of fibroblast growth factor-19 and TGR5 on intestinal glucose absorption and/or hepatic glucose metabolism, in addition to influences on peripheral insulin sensitivity, an incretin effect, an influence on energy homeostasis [12, 13] . FXR has been reported to take part in regulatlowering effect of colestimide (Table 3) . In group Co, the decrease of HbA1c was positively correlated with the baseline HbA1c value (r=0.60, P<0.0001), a result that was consistent with the finding of greater efficacy in patients with a higher baseline HbA1c (Fig. 1) .
Effect of colestimide in patients with high versus low baseline HbA1c values
In group Co, the subjects were divided according to the mean HbA1c value into group with HbA1c≤8.4% and a group with HbA1c≥8.4%. Patients in the higher baseline HbA1c group (≥8.4%) had a greater absolute mean reduction of HbA1c with colestimide therapy (-1.0%) than those in the group with a baseline HbA1c<8.4 % (-0.4%) (p=0.001).
discussion
We have previously found that colestimide reduces both the blood glucose and HbA1c. However, only a few studies have examined the hypoglycemic effect of colestimide, a new anion exchange resin, in patients with type 2 diabetes. In the present study, we examined the effects of colestimide and three different statins, (pravastatin, pitavastatin, and atorvastatin) on glycemic control in type 2 diabetic patients. We found that colestimide improved glycemic control significantly in diabetic patients, and was effective when administered either alone or in combination with their previous medications, including various antihyperglycemic agents. We also examined the clinical and laboratory factors that could be potentially associated with the glucose- risk of microvascular complications. Unfortunately, glycemic control is often inadequate in type 2 diabetic patients with hypercholesterolemia. In addition, many of the agents available to improve control may not be tolerated by a substantial number of patients or may have undesirable side effects such as weight gain, hypoglycemia, and edema that interfere with the attainment of better glycemic control and reduce compliance [24] [25] [26] [27] . For example, prolonged hypoglycemia can be induced by sulfonylurea therapy in patients with endstage renal disease [28] , and metformin is contraindicated in patients who are at increased risk of lactic acidosis such as those with hepatic or renal insufficiency. Thus, new drugs that are suitable for use by patients with hepatic or renal insufficiency are clearly needed, and colestimide is safe in such patients. In addition, cholestyramine has been reported to decrease the incidence of coronary heart disease [4, 29] , so colestimide has the potential to improve the outcome of both diabetes and hyperlipidemia, which are two major risk factors for atherosclerotic disease.
Several limitations of this study should be considered when interpreting the results. First, use of BMI as an index of obesity is limited because it is not a direct measure of body composition and may not accurately reflect body fat, especially in persons who have lost muscle mass. Second, baseline HbA1c was different between groups although affect of different baseline HbA1c levels on these results were reduce by logistic regression analysis. Third, we did not assess several factors which influence glycemic control, such as insulin resistance, adipocytokines, and inflammatory markers. Furthermore, the number of patients was limited, so investigation in a larger patient population will need to be done to identify other factors that influence glycemic control with colestimide therapy. In addition, in order to confirm the hypoglycemic effect of colestimide, crossover study, should be considered in the future.
In conclusion, colestimide effectively reduced HbA1c as well as LDL cholesterol after 3 months of treatment in patients with type 2 diabetes. The response to colestimide was not correlated with various factors, such as age, sex, BMI, or basal lipid levels.
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This work was conducted independently; no company or institution supported it financially. We appreciate Mrs. Yamagiwa and Seki for secretarial assistance. ing carbohydrate metabolism [13] . Bile acid activation of FXR has been shown to reduce expression of genes involved in gluconeogenesis including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. In addition, FXR may modulate hepatic glucose production during fasting and postprandial hepatic glucose utilization [14] [15] [16] . Since colestimide is reported to modulate bile acid content [17] , we can hypothesize that colestimide may inhibit gluconeogenesis mediated through FXR. Bile acids may also affect incretin release through activation TGR5 [18, 19] . Colestimide was shown to result in increased secretion of GLP-1 in patients with diabetes [20] . Bile acids have been also been implicated in metabolic regulation, through FXRmediated regulation of energy substrate mobilization and storage [14] . Despite these advances, further study is needed to determine the precise mechanism underlying the effect of colestimide on glucose metabolism.
Colestimide provides dual lipid-and-glucose-lowering benefits in patients with type 2 diabetes. Statin therapy should be added to lifestyle therapy for diabetic patients with overt CVD or without CVD who are over the age of 40 years and have one or more other CVD risk factors [21] . Colestimide has a different mechanism of action from that of statins and is not absorbed, making it an important addition to treatment options for hypercholesterolemia. Rhabdomyolysis is a potential severe side effect of statins that precludes their use in patients with renal insufficiency, while colestimide is safe in such circumstances. In addition, atorvastatin significantly worsens glycemic control in diabetic patients and statin therapy is associated with a slightly increased risk of the development of diabetes [22, 23] . Thus, colestimide may be a more suitable treatment for patients with type 2 diabetes.
As shown in the results, only group At showed a significant increase of both glucose and HbA1c which was compatible with previous study [22] . Recently, metaanalysis showed that statin therapy is associated with a slightly increased risk of development of diabetes, however, there were no clear difference between statins in terms of diabetes risk [23] . In addition, there are no large scale trials that the effect of statin on glycemic control in diabetic patients. Therefore, it has been a matter of recent concern whether or not statin causes the deterioration glycemic control and increase the new onset of diabetes.
The U.K. Prospective Diabetes Study [24] [25] [26] has demonstrated that reduction of HbA1c can reduce the
